Best GLP-1 Microdosing Providers (2026): Every Published Price, Ranked
A growing number of telehealth clinics offer low-dose, or “microdose,” GLP-1 protocols — small amounts of compounded semaglutide or tirzepatide aimed at appetite and metabolic baseline rather than maximum weight loss. Here is the whole field with the price each one publishes, before the long reviews.
Affiliate-funded: some of the providers below pay us a commission if you start through our link, at no extra cost to you — what we write about each one is the same either way (disclosure). Microdosing is off-label and unproven (evidence).
Charges less for less
28 providers
Publishes a named low-dose product at a lower price than its own full-dose equivalent. Taking a smaller amount genuinely costs less here, which is the structure this page is looking for.
CoreAge Rx
Doctor-reviewed low-dose GLP-1 protocols with flat pricing and built-in human support.
Main trade-off: Focused on low-dose metabolic protocols — not a full-titration weight-loss clinic
Established, physician-designed weight-care telehealth with a broad formulary, real coaching, and a new GLP-1 microdosing program.
Main trade-off: Layered pricing: the $99/mo figure is the entry/microdose tier — realistic ongoing cost runs higher, and the cheapest rates require a 3–12-month prepay
Not one flat figure · Labs optional · Pharmacy network · Dietitian included · our Found review
Both molecules in all 50 states with a microdose tier priced below the standard one — on a yearly subscription.
Main trade-off: Every published rate is a yearly subscription — the $179 headline is printed above "All doses included. Yearly subscription" and the $149 microdose tier carries the same term, so the low figure is not a monthly price you can actually buy by the month
Transparent compounded GLP-1 with a dedicated low-dose microdosing protocol, both molecules, and optional longevity add-ons.
Main trade-off: Its tirzepatide bundles cost MORE per month than paying monthly — $286 at three months, $250 at six and $244 at twelve, against $209 month-to-month — while all three are badged as savings and the 12-month one as "Best Value · Save $586". Only the semaglutide ladder actually descends, so committing longer on tirzepatide raises your monthly cost rather than lowering it
Not one flat figure · Labs optional · Pharmacy not named · our yourEra review
Sells a microdose as its own named product, priced below its own full dose.
Main trade-off: Every price is an "as low as" that depends on plan length — the microdose page shows $279 struck through above the $116, and the tiers in between are not published, so a month-to-month microdoser cannot work out their real cost
A named Microdose line with its own published price ladder, sitting well below its own full-dose line.
Main trade-off: The $109/mo the category card advertises is the 52-week prepay rung — the honest month-to-month microdose price is $149, and the gap between them is the largest here
Not one flat figure · No labs · Pharmacy not named · our Lttl review
Separates "microdose" from "low-dose" as two different products — and bills the microdose every other month.
Main trade-off: The $123/month figure is an amortisation the site does the arithmetic for — the actual charge is $246 every two months, and no monthly-billed microdose option is published, so the low headline is not a monthly bill
Sells a dedicated Microdose GLP-1+B12/NAD+ stack — in two named variants — as its own product, not a smaller dose of a standard plan.
Main trade-off: Billed per 4-week cycle, not calendar month — the real annualized cost runs roughly 8% above what the $179/$249/$339 headline figures suggest
The only provider here that publishes a milligram ceiling behind every price — and hides the microdose from anyone with a BMI over 25.
Main trade-off: The microdose SKUs are hidden from most shoppers: the funnel reveals them only when BMI is between 20 and 24.9 AND the stated goal is to lose 5 to 15 lb. Anyone at a BMI of 25 or above is never shown a microdose option at all, which is most of the people who will read this
Not one flat figure · Labs optional · Pharmacy network · Dietitian included · our Tyde Wellness review
Two named microdose products under two named physicians — behind a price grid that is entirely introductory and, on the longer plans, an average rather than a rate.
Main trade-off: On the full-dose product the three- and six-month "now" prices are blended AVERAGES that fold in a half-price first month. The advertised six-month figure works out to roughly $10/mo more than advertised from month two onward, and RestorLife does not say so next to the number
Sells microdosing cheaper than its standard program — and only as a three-month prepay, with no monthly rung to test it on.
Main trade-off: A "THREE-MONTH" PLAN HERE BILLS EVERY 10 WEEKS. Its own terms put the cycle at "every 10 weeks" on an option that ships a 12-week supply — 5.2 charges a year instead of 4, so the yearly cost is roughly 30% higher than the advertised rate suggests, and the interval appears nowhere on the plan card
A genuinely cheaper micro-dosing subscription on both molecules, billed every four weeks and priced without a milligram anywhere in the catalog.
Main trade-off: Billing is every four weeks, not monthly — 13.04 charges a year rather than 12, so the advertised $149 is really about $161 per calendar month and roughly $1,937 across a year. Nothing on the page performs that arithmetic for you
Publishes real milligram bands on both molecules — and advertises three figures side by side of which only the highest is a monthly rate.
Main trade-off: The comparison strip advertises three figures side by side of which only the highest is a month-to-month rate — the other two are three- and six-month prepay rungs presented in the same visual register, which is the single most misleading thing on the site
Not one flat figure · No labs · Pharmacy not named · Dietitian included · our WeightCare review
The clearest microdose price list here — and a flat-price guarantee written to cover the standard plans only.
Main trade-off: The flat-price guarantee is written for the standard semaglutide and tirzepatide plans only. Avono never says the $179 microdose price holds as the microdose is titrated upward, which is the single thing a microdose buyer most needs in writing
Month-to-month microdosing with no commitment tier at all — and you cannot know which of four drugs the price buys until after you pay.
Main trade-off: You cannot know what molecule the $129 buys. One microdose price covers four different products — semaglutide or tirzepatide, oral or injection — and the clinician selects from them after payment is authorized, so the buyer commits before the drug is chosen
Prices a microdose $30 below its own full dose, misspells it on the only page that sells it, and publishes no milligram for either.
Main trade-off: Every GLP-1 figure is a "starting at" price with no milligram, no ladder and no plan length — the $249 microdose could buy any quantity of drug, and nothing on the site narrows it
Not one flat figure · Labs optional · Pharmacy not named · our NuBloom review
Every advertised figure on the site is a twelve-month prepay, and two of them exist at no tier of its own checkout.
Main trade-off: Every advertised price is a twelve-month prepay. The headline microdose figure is nearly $1,000 charged up front, and the true month-to-month microdose rate is two and a half times the number on the page
Not one flat figure · Labs optional · Pharmacy not named · Dietitian included · our Measured review
Publishes the dose its microdose price buys, names its pharmacy, and sells the vial for $25 — then charges the visit fee again on every refill.
Main trade-off: The $25 headline is the drug only — the flat $39 medical visit fee and $15 shipping bring a first order to $79, and the visit fee recurs on refills rather than being a one-time onboarding charge
Prices a real microdose against a named milligram — and never says what period the "/mo" covers.
Main trade-off: THE "/mo" HAS NO PERIOD ATTACHED. Neither price on the microdosing page states a plan length, a billing cadence or whether the rate requires a commitment — and this site has repeatedly found that an unqualified "/mo" in this category is a prepay rung rather than a standing rate. Treat both figures as unverified monthly rates until Maximus says what they buy
Prices the vial your dose needs rather than a plan — the rare place where a quarter dose really does cost about a quarter.
Main trade-off: Every figure is an estimate, not a quote — "Estimated cash price only. Your exact dose, vial size, and cost are confirmed by a licensed provider at your free consult — before you pay anything"
States plainly that its advertised figures are based on the lowest dosage and that higher doses may cost more. On a general ranking that is a warning; for someone staying small it is the one model that bills accordingly.
Breeze Meds
Prices its plans off the LOWEST dose — the one pricing model here that does not penalize taking less.
Main trade-off: No pricing at all on the public site — the molecule behind its "from $199" is never named, and tirzepatide figures appear only inside the intake
Publishes an eleven-rung price ladder with a milligram figure against every rung — and advertises two entry prices that appear on none of them.
Main trade-off: The main GLP-1 page advertises "Starts at $199/month" and $199 appears at no rung of Elara's own published ladder — the cheapest semaglutide price it actually publishes is $249 at 0.2 mg/week. That page carries exactly one dollar figure and no milligram figure at all
Prices each vial by the dose it holds, so a 0.25 mg/week microdose buys ten weeks of supply for the price of a five-week one.
Main trade-off: The advertised figures are PER-VIAL prices whose supply duration swings between four and ten weeks depending on the dose, so no number on the page is a monthly rate and two of them cannot be compared without doing the arithmetic yourself
Not one flat figure · Labs optional · Pharmacy not named · Dietitian included · our Aspire Health review
One of the few here that charges by the dose — and the only saving it advertises is measured against a higher dose than the one you are buying.
Main trade-off: The bundle block advertises "Starts at $199 $159", but $199 is not a former price of the 0.25 mg rung — it is what Coby charges for the NEXT dose up, 0.50 mg. The saving is displayed against a higher dose than the one being sold
Quotes 0.22 mg — below the label's own starting dose — and bills its "1-month plan" every 23 days.
Main trade-off: THE "1-MONTH PLAN" IS NOT MONTHLY. Its own checkout data sets the billing interval to 23 days, so a plan advertised at "$140/mo" with "$140 monthly renewal" recurs 15.87 times a year — about $2,222 annually against the $1,680 that twelve monthly charges would imply, roughly 32% more. The interval appears nowhere in the plan's visible label
Publishes a full dose-by-dose price table for both routes — and charges the same for 0.1 mg as for 0.5 mg.
Main trade-off: Within the lowest injectable band the price is flat: 0.1 mg, 0.25 mg, 0.35 mg and 0.5 mg are all $165.90, so a patient deliberately taking a fifth of the band's top dose pays exactly what its top dose costs. The ladder rewards staying under 0.75 mg, not staying low
Publishes an actual milligram against an actual price — and never says how long it lasts.
Main trade-off: NO PACK SIZE, TABLET COUNT OR DAY SUPPLY IS PUBLISHED FOR ANY ITEM, so $199 for a 1 mg tablet cannot be turned into a monthly cost and nothing downstream of that can be computed
Prints every milligram rung in public, and the starter dose is the cheapest one.
Main trade-off: A "MONTH" HERE IS FOUR WEEKS, AND THE SITE SAYS SO. "Billed every 4 weeks" is 13 charges a year, so the 2.5 mg plan costs $2,912 a year — about $242.67 per calendar month against a printed $224, roughly 8% more
Prices a starter dose below every other dose — and calls twelve weeks three months.
Main trade-off: THE "3 MONTH" PLAN SHIPS 12 WEEKS, NOT 3 CALENDAR MONTHS. $447 over 12 weeks is $161.90 per 4-week cycle against the "$149/ month" printed on the card
Names hiding dose pricing as the thing it refuses to do — then prints the whole ladder.
Main trade-off: THE SEMAGLUTIDE LADDER IS LABELED IN MILLILITERS, NOT MILLIGRAMS — ".25-1ml/week Dosage", "1.5-1.75ml/week Dosage", "2-2.5ml/week Dosage" — while the same site's FAQ writes the range as "(.25-2.5mg)". The unit on the price table is wrong, and the two cannot both be right
A real milligram ladder, printed on the tile — and every advertised rate is six months you cannot leave.
Main trade-off: THE ADVERTISED RATES ARE A SIX-MONTH NON-CANCELABLE COMMITMENT. Every membership tier is labeled that way, so the $119 headline is six months you cannot leave — and the figures quoted for this provider in third-party directories are those locked rates, which understate the month-to-month cost by 40 to 51%
The one medication price here that actually rises with the dose — billed separately from the membership.
Main trade-off: THE MEMBERSHIP DOES NOT INCLUDE THE MEDICINE. A self-pay patient pays $74/month for Med+ plus $149 to $299 for the medication — $223 to $373 a month in total, a sum the site never performs in one place
The only price ladder here that falls when your dose does — and it is brand-name drug at a retail counter, not a plan.
Main trade-off: THIS IS NOT A COMPOUNDED PRODUCT OR A TELEHEALTH PLAN. It is a coupon against brand-name drug at a retail counter, so you need a prescriber of your own and the medication is dispensed at a pharmacy rather than shipped to you
Not one flat figure · No labs · Pharmacy not named · our GoodRx review
$199/fill Wegovy pens at 0.25–0.5 mg, $349 at 1 mg and up
Publishes a milligram-per-week price ladder on the homepage, with no quiz in the way.
Main trade-off: THE RENDERED COPY NEVER NAMES THE MOLECULE. What you buy is "Personalized GLP-1" or "Personalized GLP-1/GIP +B12"; which drug that is can only be inferred from the milligram ladder and the page address
Caps its cheapest product at 1 mg and prints a price on it — then never says what period the price covers.
Main trade-off: THE FOUR DOSE-CAPPED PRODUCTS NEVER SAY WHAT PERIOD THE PRICE COVERS. "$199" for "Up To 1 mg" could be a month, a course or a single vial, and nothing on the page says which — which makes the cheapest rung here impossible to compare against anything
Publishes a dated dose-by-pharmacy price table, so a quarter dose can be costed exactly before signing up.
Main trade-off: THE BUNDLED PLANS ARE FLAT WITHIN THEIR CEILING, so a patient on 0.25 mg on Basic pays the full bundled rate for medication that costs $67 per four-week fill on the à la carte path. Which path you pick matters more here than which provider you pick
Charges by the milligram on both molecules — then advertises a rate in its own nav banner that no monthly plan actually sells for.
Main trade-off: The site-wide banner advertises "GLP-1s starting at $149.99/month", but no month-to-month GLP-1 is sold at that price. It exists only as the tirzepatide 2.5 mg three-month plan, whose own text says it "Cannot be canceled mid-plan" — a three-payment commitment quoted as a monthly rate
Not one flat figure · No labs · Pharmacy not named · our Arc-1 review
Prints a price against every milligram rung and sells each month outright — then offers a "discount" subscription that costs more over a year than paying full price.
Main trade-off: The "discounted" subscription costs more per year than paying full price twelve times: $100 every 23 days is 15.87 charges, about $1,587 a year, against $125 × 12 = $1,500
Publishes total milligrams against its tirzepatide rungs — and squeezes them so tightly that holding low saves you almost nothing.
Main trade-off: The tirzepatide rungs are compressed. 216 mg costs $549 against $499 for 144 mg, so half again as much drug costs about a tenth more money — holding at a low dose saves you almost nothing against the top rung
Sets your price from the dose you start at, lets you pick the pharmacy that fills it, and then holds that rate as the dose climbs.
Main trade-off: The price lock is tied to continuous membership rather than to the patient: "your rate stays the same as long as your membership remains active". A break in treatment is not free
Not one flat figure · No labs · Pharmacy not named · our Mondae review
One of the few here that charges extra for the top of the dose range — and never says where the base membership caps out.
Main trade-off: The milligram ceiling of the base $275 and $445 memberships is never stated. You learn what the high-dose tier buys without learning what the standard tier covers
Names the pharmacy that fills every prescription — then prices only the bottom rung of the ladder.
Main trade-off: EVERY PRICE IS A FLOOR. All four products are advertised "as low as", and no higher-dose rung is published at any figure, so someone holding at a low dose cannot tell whether staying low saves anything
Publishes two different prices for the same tirzepatide on a single page load.
Main trade-off: TWO PRICES FOR ONE PRODUCT. Compounded tirzepatide is published at $329/month in one place on the homepage and "Starting at $283/mo" in another, in the same render — reproduced on a second fetch, so it is not a caching artifact
Publishes a price for a microdose track, but no standard-dose price alongside it — so you can cost the low dose, you just cannot see what it saves you.
Lemonaid Health
Microdose-forward telehealth offering low-dose semaglutide and tirzepatide tracks.
Main trade-off: Medication is billed separately from the visit — total cost stacks
Sells both molecules as named Microdose Programs — beside an ivermectin shelf that has nothing to do with either.
Main trade-off: The same storefront retails ivermectin and an ivermectin + mebendazole combination alongside the GLP-1 line; the FDA has publicly warned against using ivermectin outside its approved labels, and a metabolic prescriber stocking it is a judgment signal about the whole catalog
The only thing it sells is a microdose — and it prints outcome ranges for one that no trial has produced.
Main trade-off: The homepage prints expected nausea rates, lean-mass retention and result ranges for a 1 mg microdose — figures extrapolated from full-dose and observational data, not measured on the protocol being sold, which is exactly the overreach this site was built to flag
Four separately named microdose products, and not one month-to-month price published for any of them.
Main trade-off: Alan publishes no month-to-month price for ANY microdose product. Every microdose figure on the site is either footnoted as paid upfront with a six-month plan or carries no tier label at all, so a reader cannot learn what one microdose month costs — on a four-product microdose line marketed as its longevity offering
Sells a named microdose at a published price — and the weekly total behind it is three times the standard starting dose.
Main trade-off: THE WEEKLY TOTAL IS NOT A MICRODOSE. At 0.25 mg per dose three times a week, the weekly exposure is 0.75 mg — three times the 0.25 mg/week that is the standard starting dose of semaglutide. The word "microdose" here describes the size of each injection, not the amount of drug taken per week, and a reader who assumes otherwise would be taking more drug than a conventional starting protocol, not less
Prices a real microdose line below its standard plans — then flattens that tier too.
Main trade-off: THE MICRODOSE TIER IS ITSELF FLAT. Both microdose SKUs carry the same "Flat pricing at every dose" badge as the standard products, so a patient quartering the $99 microdose pays the same $99 as one taking all of it
Runs a genuinely cheaper microdose tier — and never says how many milligrams it buys.
Main trade-off: NO MILLIGRAM FIGURE IS PUBLISHED AGAINST ANY PRICE. The microdose tier is genuinely cheaper, but "microdose" here names a product rather than an amount, so what a quarter dose costs still cannot be computed
Not one flat figure · No labs · Pharmacy not named · our NiceRx review
$199/mo semaglutide, $299 tirzepatide · microdose from $149
Prices a low dose lower on three named products — and closes the long commitments to anyone who buys them.
Main trade-off: THE MICRODOSING PLANS STOP AT 12 WEEKS. There is no 24-week or 52-week microdosing rung, so the deepest prepay discounts are available only if you buy a standard dose
The one seller here with a named lowest-dose tier that prints the milligram on the tile — and prices it lower.
Main trade-off: THE MAIN TIERS ARE FLAT ACROSS THEIR WHOLE RANGE, so a patient holding 0.25 mg on the standard semaglutide plan pays what one at 2.5 mg pays. The lowest-dose tier is the way out, and it is a separate product with a stated ceiling
One figure regardless of how much drug you take. Reassuring if you expect to titrate upward, and the least economical structure on this page if you do not: a quarter dose costs what a full one does.
Trimi
A microdose-first telehealth program built around low, longevity-oriented GLP-1 dosing at one flat monthly price.
Main trade-off: Compounded-only — no brand-name Wegovy or Zepbound pathway, and compounded GLP-1s are not FDA-approved
Promises in writing that the price never moves when the dose does — on standard-dose plans, with no microdose product behind the promise.
Main trade-off: No microdose or low-dose GLP-1 product of any kind — the word does not appear anywhere on the site or in its application bundle, so starting low here means self-directing a smaller amount inside a standard-dose plan at the standard plan's price
One of the few rankings here with a purpose-built microdose SKU for both molecules — priced the same as, or higher than, its own full-dose plans.
Main trade-off: Microdosing here is not a cheaper way in: the microdose SKUs are priced identically to the full-dose products at every rung they share, and because the microdose line has no twelve-month tier its best possible rate is HIGHER than the full-dose product's — $229 against $199 for semaglutide, $319 against $299 for tirzepatide. You pay the same or more for less medication
Prices its whole catalog in public and sells brand-name alongside compounded — then charges one figure whatever dose you are on.
Main trade-off: The price does not move with the dose. Its intake collects a weekly semaglutide strength — 0.25, 0.5, 1, 1.5 or 2.5 mg — but there is no dose dimension in its commerce layer at all: one price per product per term. Someone held at 0.25 mg pays the same $199/mo as someone at 2.5 mg, for a tenth of the drug
One flat month-to-month figure covering every dose of a tirzepatide-only program, behind a first-month introductory price.
Main trade-off: One figure covers every dose — the buy box reads "Monthly Supply (All doses)" — so someone deliberately holding at a starter dose is billed exactly what someone at the top of the range is billed, and there is no cheaper low-dose product to move to instead
Runs a real eight-SKU microdose line — and prices the tirzepatide the same at every dose.
Main trade-off: "ZERO SIDE EFFECTS" HEADLINES THE MICRODOSE PAGE, under the subhead "Zero side effct for 70%+ of members" — the typo is theirs. An unqualified zero-side-effect claim for a compounded GLP-1 is not something any evidence supports, and it sits directly above the safety notice that warns about thyroid tumors
Publishes the whole billing-cycle table so the standing rate is recoverable — and splashes the twelve-month rate across the homepage anyway.
Main trade-off: ONE PRICE AT EVERY DOSE. A patient holding at a quarter dose pays exactly what a full-dose patient pays, and no low-dose product is published to move to instead
Publishes a real per-dose ladder — and then prices its microdose above the ladder's bottom rung.
Main trade-off: Its microdose costs MORE than its own starting standard dose — flat $199 for microdose semaglutide against $189 for the 2.5 mg/wk first rung, and $229 against $199 on tirzepatide — so deliberately taking less is billed at a premium here, the opposite of what a low-dose reader wants
Offers a microdose as a dosage type — at the same price as the full one, billed a quarter at a time.
Main trade-off: Choosing the microdose does not lower the price — it is a dosage type inside the same product at the same from-price, so a fraction of the drug costs what a personalized full dose does
Sells a GLP-1 Microdose as a first-class catalog product — and charges $10 a month more for it than for the standard-dose injection.
Main trade-off: The microdose costs MORE than the standard semaglutide injection — $195 against $185 month-to-month, and $555 against $495 over three months. Choosing less drug is a $10-a-month premium here, on Näky's own published figures
A separately titled microdose product whose price ladder is byte-identical to the full-dose one, rung for rung.
Main trade-off: Microdosing costs exactly what the full dose costs — $129/mo either way on semaglutide, $179/mo either way on tirzepatide, across all four rungs of an identical ladder. You pay full-dose money for less drug, and nothing on either page says so
Prices its microdose above its own headline full-dose figure — and never publishes the plan length behind either.
Main trade-off: Microdosing is advertised at $134/mo, ABOVE the $127/mo full-dose headline on the same product grid — the lower dose is the more expensive line item on Woodwork's own page
Not one flat figure · Labs optional · Pharmacy not named · our Woodwork review
Two separately titled microdose products, every price a four-month prepay, and a "lowest price ever" with no price published to compare it to.
Main trade-off: Microdosing Tirzepatide at $159/mo costs MORE than the general GLP-1s Rx program at $139/mo on the identical four-month plan length — the microdose line is the premium product here, not the economy one
Headlines a microdose price that is purchasable at no tier, and quotes both standard products at their six-month prepay rung.
Main trade-off: The microdose page headlines a discounted figure that is not purchasable at any tier — the cheapest real microdose plan is $174, and the advertised price does not exist as a buyable plan
A dose-scaled tirzepatide ladder next to a flat "any dose" semaglutide price — and a named microdose that saves four dollars.
Main trade-off: The named microdose saves four dollars. It is $245/mo against $249/mo for the lowest rung of the standard tirzepatide ladder — and unlike that rung, it publishes no milligram figure at all, so you are paying almost the same money for a dose you cannot see
Runs dedicated micro-dose pages for both molecules that charge exactly what the full-dose pages charge.
Main trade-off: The micro-dose costs exactly what the full dose costs — $169 semaglutide and $249 tirzepatide on both pages — so a microdoser buys a fraction of the drug for the full-dose price, and the dedicated micro-dose page never says so
States "same price at every dose" in its own words, and publishes no dose range for the sentence to cover.
Main trade-off: Sells no microdose product at all. A microdoser pays the full $160 or $199 for whatever fraction of the drug is prescribed, with no lower tier to step down to — and "same price at every dose" is precisely the sentence that guarantees it
Publishes the exact dose ceiling and week-by-week titration behind its microdose price — and charges $26 more across a year for it than for the unrestricted plan.
Main trade-off: The Micro-Dose costs essentially what the unrestricted program costs — $197 against $199 — while capping you at roughly a fifth of the maximum dose. And across twelve months it costs MORE, because the $50 first-month credit applies to the standard semaglutide and tirzepatide programs and explicitly excludes the Micro-Dose: $2,364 against $2,338
Its microdose costs more month-to-month than its standard plan — and both are advertised at prepay rungs where the order reverses.
Main trade-off: The semaglutide microdose costs MORE month-to-month than standard semaglutide — $184 against $179 — so choosing the gentler product is a premium for less drug. The site never discloses this, because it advertises both products at their twelve-month prepay rungs, where the ordering reverses
Not one of its advertised microdose prices is purchasable, and the microdose page is a copy of the semaglutide page with the same intake link.
Main trade-off: None of Zera's advertised microdose prices are purchasable. The homepage, the product hero and the product page's own plan table each quote a different figure, and the checkout charges a first month and a standing rate that match none of them
Publishes the dose range its flat price covers — which is what makes "same price all doses" checkable, and damning.
Main trade-off: THIS IS THE STRUCTURE THIS SITE EXISTS TO FLAG, and TMates publishes enough to prove it: a patient deliberately holding 0.25 mg/week pays exactly what a patient at 2.4 mg pays — nine to ten times the drug for the same money. The badge reads as a feature and is a cost to anyone intending to stay low
A genuinely low flat rate, and no published dose anywhere to measure it against.
Main trade-off: NO DOSE IS PUBLISHED AGAINST EITHER PRICE, so "each flat monthly rate" cannot be checked. A flat rate is only good news to a microdoser if you know what the full-dose alternative would be, and Sunlight publishes neither end of that comparison
States the flat structure outright — and the only page meant to publish the prices is a crash.
Main trade-off: ONE PRICE AT EVERY DOSE IS THE STRUCTURE THIS SITE EXISTS TO FLAG. A patient deliberately holding 0.25 mg/week pays the identical $299 as one at the top of the range. TrimRx is unusually candid about it, and candour does not change the arithmetic
Names all four of its pharmacies — and publishes three different tirzepatide prices.
Main trade-off: ONE PRICE AT EVERY DOSE IS THE STRUCTURE THIS SITE EXISTS TO FLAG. "Your price doesn't go up when your dose does" cuts both ways — a patient deliberately holding a quarter dose of semaglutide pays the identical $119 as one at the top of the range
Flat at every dose — and honest enough to print the month-to-month rate beside the annual one.
Main trade-off: ONE PRICE AT EVERY DOSE IS THE STRUCTURE THIS SITE EXISTS TO FLAG. "Same Low Price at Every Dose Level" means a patient deliberately holding a quarter dose pays the identical $199 as one at the top of the range
The most explicit flat-dose promise here — which is exactly the wrong promise for a low dose.
Main trade-off: ONE PRICE AT EVERY DOSE IS THE STRUCTURE THIS SITE EXISTS TO FLAG. "Same price at any dose... no dose-stage upcharges" means a patient deliberately holding a quarter dose pays the identical $139 as one at the top of the range
Answers the dose-price question as a yes-or-no FAQ, and publishes what happens when the promo ends.
Main trade-off: ONE PRICE AT EVERY DOSE IS THE STRUCTURE THIS SITE EXISTS TO FLAG. "Does the price increase with the dose? No!" means a patient deliberately holding a quarter dose pays the identical $149 as one at the top of the range
Flat at every standard dose — and it names the milligram where that stops being true.
Main trade-off: ONE PRICE ACROSS THE STANDARD RANGE IS THE STRUCTURE THIS SITE EXISTS TO FLAG. "Your price stays flat at every standard dose" means a patient deliberately holding a quarter dose pays the same $299 per 4 weeks as one just below the maximum
Publishes every strength it sells beside the one price they all cost.
Main trade-off: ONE PRICE AT EVERY DOSE IS THE STRUCTURE THIS SITE EXISTS TO FLAG. "Your cost remains the same, even as doses change" — a patient holding 0.25 mg pays the same $299 as one at 2.4 mg, and Vyora publishes both strengths so the arithmetic is checkable
Prints "Same price, every dose" above its own price table — and the two tables on that page disagree.
Main trade-off: ONE PRICE AT EVERY DOSE. A patient deliberately holding a quarter dose pays the same $179 as one at the top of the range, and the difference is medicine bought and never used
Says "Uniform cost for all doses" on the card itself — and puts a tier that buys no medicine in the same grid.
Main trade-off: ONE PRICE AT EVERY DOSE, in the company's own words: "Regardless of the medication dose for your treatment plan, the price remains the same!" A quarter dose costs the same $298 as a full one
The fullest price disclosure here, on a structure that charges a quarter dose like a full one.
Main trade-off: ONE PRICE AT EVERY DOSE: "Same Price, Any Dose … No surprise increases." A quarter dose of semaglutide is billed the same $175 as a full one
Consistent about the flat-dose rule, and inconsistent about the rate it applies to.
Main trade-off: ONE PRICE AT EVERY DOSE. A quarter dose is billed like a full one — Heros is candid about it, and candour does not change the arithmetic
Four pharmacies named to the street address — and not one milligram published against the price.
Main trade-off: ONE PRICE AT EVERY DOSE, so a quarter dose is billed like a full one — and with no milligram figure published, there is no way to tell how much drug the rate buys in the first place
Prices a named microdose line below its main program — then tells you on the same page it isn't available yet.
Main trade-off: ONE FIGURE AT EVERY DOSE ON THE MAIN PROGRAM. "All doses included" means a patient holding a quarter dose pays exactly what a patient at the top of the range pays, and the difference is drug bought and never injected
Prints the crossed-out standing rate beside the sale price — and the figure it advertises is a six-month prepay.
Main trade-off: SAME PRICE ANY DOSE IS THE STRUCTURE THIS SITE EXISTS TO FLAG. A patient holding a quarter dose is billed what a patient at the top of the range is billed, and the gap is medication bought and never injected
Sells a flat all-doses subscription and a per-milligram vial ladder on the same page.
Main trade-off: THE SUBSCRIPTIONS ARE ALL-DOSES, so on a plan a quarter dose costs exactly what a full dose costs. The per-milligram vials are the way out of that, and they are a separate product with no ongoing care attached
Publishes every strength it dispenses, down to 0.2 mg — and charges the same for all of them.
Main trade-off: ALL DOSES ARE PRICED THE SAME, in the seller's own words: "All doses are priced the same, so your plan is guided by what's medically appropriate, not cost." The 0.2 mg strength is billed at the same rate as 1.2 mg — six times the drug for identical money
Promises the price is locked for life at every dose, and sells the same tirzepatide at two prices at once.
Main trade-off: ALL DOSES INCLUDED, WITH THE PRICE LOCKED FOR LIFE, means a quarter dose is billed exactly as a full one — and stays that way for as long as you stay
Puts the month-to-month rate in the same table as the prepay rungs, then headlines a figure that matches neither.
Main trade-off: THE SAME PRICE APPLIES AT EVERY DOSE, so a quarter dose is billed at the full-dose rate and the difference is drug you paid for and did not inject
Shows both the monthly figure and the sum actually charged on every rung — and one price covers every titration dose.
Main trade-off: "Same price applies across all titration doses within a plan", so a quarter dose is billed exactly as a full one and the difference is medication bought and never used
Says "Same price at every dose" in one unambiguous sentence — and advertises a rate that is the twelve-month prepay rung.
Main trade-off: ONE PRICE AT EVERY DOSE IS THE STRUCTURE THIS SITE EXISTS TO FLAG. A patient deliberately holding at 0.25 mg/week pays the same $296 as one at the top of the range. Elevated is candid about it, and candor does not change the arithmetic
The only provider here that shows what the drug itself costs — and the drug line does not move when your dose does.
Main trade-off: ONE PRICE AT EVERY DOSE. The medication line inside that itemized breakdown does not move when the dose does, so a patient holding at a quarter dose pays the full-dose medication charge
Publishes the standard rate its discount is measured against and rules out prepayment — then charges the consultation outside the monthly price.
Main trade-off: One monthly figure per molecule with dose changes folded into the membership, so a patient holding at a quarter dose pays what a full-dose patient pays. KERNX never states this in a sentence, which makes it harder to check than at providers that say it outright
Says "Same price, every dose" and prints the whole dose ladder beside it — then headlines an annual rate as if it were monthly.
Main trade-off: ONE PRICE AT EVERY DOSE, stated outright. A patient holding at 0.25 mg/week pays the same as one at 2.5 mg, and Lumen prints both ends of that range next to the single figure
Names its prescribing clinicians with their NPI numbers — and runs a "same price every month" hero directly above a countdown headed "Price increases in".
Main trade-off: ONE PRICE AT EVERY DOSE, stated outright. A patient deliberately holding at a quarter dose pays exactly what a full-dose patient pays, and no low-dose product is published to move to instead
Words the flat-dose promise better than anyone here — and pins it to a six-month prepay rate rather than the one you would actually pay.
Main trade-off: ONE PRICE FROM THE STARTER DOSE TO THE HIGHEST. A patient deliberately holding low pays exactly what a top-of-range patient pays, and the site says so in as many words
The only provider here that ties a flat price to named milligram rungs — and the only one selling the FDA-approved brand rather than a compound.
Main trade-off: ONE PRICE ACROSS EVERY NAMED RUNG. A patient at 1.5 mg pays what a patient at 25 mg pays, and the difference is medication bought and never taken
Names a pharmacy with its state board license number and says its cheap figure is annual in the same sentence — and still charges one price at every dose.
Main trade-off: ONE PRICE AT EVERY DOSE. "Your price never changes as your dose is adjusted" cuts both ways — a patient holding at a quarter dose pays what a full-dose patient pays
Prints the exact milligram range its flat price covers, names its pharmacy with a street address — and publishes three different current prices on one screen.
Main trade-off: THE STANDING RATE IS NOT SETTLED. "From $99", "From $149" and "Starting at $179.99/Month" all appear as current on the same page, and the highest is 82% above the lowest. Nothing on the page reconciles them
Puts "Flat Rate Pricing No Matter the Dose" inside the plan card — and hides the tirzepatide rate you will actually pay behind a toggle.
Main trade-off: ONE PRICE AT EVERY DOSE. Someone deliberately holding at 0.25 mg/week pays the same $249 as someone at the top of the range, and the difference is medicine bought and never used. Peak states the structure plainly, which is more than most manage, and stating it does not change the arithmetic
Sells "one flat price" at every dose — then charges a third pair of figures that appears nowhere on its own site.
Main trade-off: ONE FLAT PRICE AT EVERY DOSE — "Two proven options. One flat price. No tiers, no upsells, no insurance games." A patient holding at a quarter dose pays exactly what a full-dose patient pays, and the difference is medicine bought and never used
Commits to the same price for every dose — while every figure it advertises is either a first month or a year paid up front.
Main trade-off: SAME PRICE FOR EVERY DOSE. A patient holding at 0.25 mg pays what a top-of-range patient pays, and the difference is medicine bought and never used. Velvet is candid about the structure, and candor does not change the arithmetic
The rare flat-price seller that says which milligrams "all doses" means — and every figure it advertises is a year paid in advance.
Main trade-off: ONE PRICE AT EVERY DOSE. Someone holding at 0.25 mg pays what someone at 2.5 mg pays, and the difference is medicine bought and never used. NewSelf is unusually specific about which doses that covers, and specificity does not change the arithmetic
Flat at every dose, stated in its own page data — and the month it is priced in is four weeks long.
Main trade-off: The billing unit is four weeks, not a calendar month, so the charge lands thirteen times a year and the annual cost runs about 8% above the monthly label.
Promises one price at every dose and keeps it — then quietly defines the month as four weeks.
Main trade-off: THE MONTH IS FOUR WEEKS. "From $149/month" buys "4 weeks of medication", which recurs 13 times a year rather than 12 — about $1,937 a year on semaglutide against the $1,788 the headline implies, and about $2,548 against $2,352 on tirzepatide
Flat pricing at every dose, published per product — and a rebrand mid-flight that a reader needs to know about.
Main trade-off: The brand is changing names mid-flight. The site announces "Piper is now Polly" while the domain, its directory listings elsewhere and much of the copy still say Piper, so a patient checking reviews may not be reading about the same entity they are buying from
Promises the same price at every dose, then heads one of its two cards "Starting at".
Main trade-off: The tirzepatide card is headed "Starting at $249" while its own body says "All doses just $249/month" — the page contradicts itself about its own price.
Physician-founded telehealth with transparent, all-inclusive GLP-1 pricing, injectable and oral capsule routes, and coverage in all 50 states.
Main trade-off: Its tirzepatide bundles cost MORE per month than paying monthly — $286 at three months, $250 at six and $244 at twelve, against $209 month-to-month — while all three are badged as savings and the 12-month one as "Best Value · Save $586". Only the semaglutide ladder actually descends, so committing longer on tirzepatide raises your monthly cost rather than lowering it
LegitScript-certified, low-friction compounded GLP-1 at $149/$199 with a real brand-name Wegovy/Zepbound backup path.
Main trade-off: Standard-dose compounded GLP-1, not a dedicated microdosing program — starting low means self-directing a lower dose within a standard plan
Broad compounded storefront whose every advertised "from" figure is a twelve-month prepay rung — the month-to-month rates are more than double.
Main trade-off: Every advertised "from" figure on the page this link lands on is a TWELVE-MONTH rung billed as a single payment, not a monthly rate. The hero reads "from $159/mo" and the entry cards read "FROM $199" and "FROM $249"; the rates actually charged month to month are $279 for the semaglutide injection, $349 for the tirzepatide injection and $199 for the drops
The Bodybuilding.com fitness brand's new compounded-telehealth arm — budget sema/tirz bundles with publicly listed pricing.
Main trade-off: Its tirzepatide bundles cost MORE per month than paying monthly — $286 at three months, $250 at six and $244 at twelve, against $209 month-to-month — while all three are badged as savings and the 12-month one as "Best Value · Save $586". Only the semaglutide ladder actually descends, so committing longer on tirzepatide raises your monthly cost rather than lowering it
A broad physician-prescribed telehealth catalog — TRT, GLP-1, NAD+, sermorelin and more under one account — priced at standard, not micro, doses.
Main trade-off: No confirmed low-dose or microdose SKU — the tirzepatide plan is a 60mg maintenance-range dose, not a microdose, and the GLP1 + B12 semaglutide tiers are standard plans, not a dedicated start-low product, which is a real fit gap for a reader here specifically to microdose
Not one flat figure · Labs optional · Pharmacy not named · our Peter MD review
The best-documented company here — six pharmacies and two NPI-verified clinicians named in public — selling no low-dose tier a reader can actually buy.
Main trade-off: There is no purchasable low-dose or microdose tier here — not on any screen, at any rung, by any path that was walked — and no dose selector appears anywhere before purchase. Pallas sells full-dose compounded semaglutide and full-dose compounded tirzepatide and nothing beneath them, so starting small means asking for less inside a full-dose plan and paying the full-dose plan's price
Advertises three entry prices that its own FAQ contradicts by up to 67%, on a plan billed thirteen times a year.
Main trade-off: The three product cards advertise entry prices while the FAQ on the SAME PAGE puts the month-to-month rates at $249, $339 and $279 — the semaglutide headline understates its own standing rate by 67%, and the commitment length that would buy the advertised figure is disclosed nowhere
Not one flat figure · Labs required · Pharmacy not named · Dietitian included · our Fitstry review
Advertises GLP-1 microdosing in the navigation of every page on the site, and the link goes to the testimonials page.
Main trade-off: The "GLP-1 Microdosing" navigation item is a dead link. It resolves to a blank route that renders the testimonials page, so the microdose offering advertised in the menu of every page on the site does not exist as a product, a page or a price
Publishes two different standing prices, and which one you see depends on your device.
Main trade-off: THE HOMEPAGE PRICES DIFFER BY SCREEN SIZE. Desktop, tablet and widescreen visitors see a standing rate of $349/month; phone visitors see $299/month for the same program — the two are quoted $50/month apart
Publishes the standing rate beside every teaser — then publishes three of them.
Main trade-off: NOT ONE MILLIGRAM FIGURE APPEARS AGAINST ANY PRICE on /weight-loss or /all-treatments, so what a low dose costs cannot be established before paying
Not one flat figure · No labs · Pharmacy not named · our Layla review
$297/mo semaglutide, $399 tirzepatide (a third block says $449)
Publishes a titration schedule in milligrams, and never attaches a price to any of them.
Main trade-off: THE PLAN SET VARIES ONLY BY DURATION, NEVER BY DOSE — four semaglutide plans, four tirzepatide plans, no dose variants at all — so what a low dose costs cannot be established
One of the fullest public price lists here, and it never mentions dose.
Main trade-off: WHETHER THE PRICE MOVES WITH THE DOSE IS NEVER ADDRESSED, in either direction, despite "Dose adjustments as needed" appearing on almost every tile
Two plain prices, a real clinic address — and a headline that compresses seventeen months into four.
Main trade-off: NOT ONE MILLIGRAM FIGURE APPEARS ANYWHERE ON THE PAGE, and no dose statement of any kind is published in either direction, so what a low dose costs cannot be established before paying
Sells a daily sublingual GLP-1 on a microdosing rationale — and publishes no ladder behind the price.
Main trade-off: THE DOSE-TO-PRICE LADDER IS NOT PUBLISHED. The card says pricing depends on dosing and then quotes one figure, so what a low dose actually costs cannot be worked out before you pay
Charges once rather than monthly, and attaches no dose to any of its prices.
Main trade-off: IT SELLS COMPOUNDED RETATRUTIDE at $479, badged "Popular". Retatrutide is not approved by the FDA for any indication, which is a different decision from buying a compounded copy of an approved drug
Flat price · Labs optional · Pharmacy not named · our Pepti review
$239 one-time for a ~30-day tirzepatide supply, no subscription
Says plainly that the subscription does not cover the medicine — and never publishes what the medicine costs.
Main trade-off: THE MEDICATION COST IS NOT PUBLISHED AT ALL, and the range offered instead spans two orders of magnitude — "$10 to $900 per month". What treatment costs here cannot be worked out in advance from anything on the site
Names the compounding pharmacy against every single price, and never publishes a milligram.
Main trade-off: NO MILLIGRAM FIGURE APPEARS ANYWHERE ON THE PRICING PAGE, so what a quarter dose costs here cannot be worked out before you pay. Every price is attached to a course length and a pharmacy, never to a dose
Names both fulfilling pharmacies and holds your card until a clinician approves — and publishes not one milligram figure against either price.
Main trade-off: NO DOSE IS PUBLISHED AGAINST EITHER PRICE. Not one milligram figure appears anywhere near a GLP-1 price on the site, so a reader deliberately holding at a quarter dose cannot tell what that quarter dose is costing them until after the intake
One of the few to attach a milligram to a price — then publishes no second rung to compare it against.
Main trade-off: THE ADVERTISED FLOOR DOES NOT EXIST. "As low as $199 per month" and "less than $7 per day" are buyable at no commitment length: the cheapest rate is $202.25/month and requires $2,427 up front, and the month-to-month rate of $369 is about $12 a day
Not one flat figure · No labs · Pharmacy not named · Dietitian included · our Revive Meds review
Names the pharmacy that fills the vial, and prices every product against a struck-through rate.
Main trade-off: Every product is priced against a struck-through higher figure, so the markdown is the permanent state of the page rather than an offer.
A low-dose lane may exist, but nothing public says what it costs — so the one question this page exists to answer cannot be answered before you sign up.
Care Bare Rx
Oral tirzepatide as well as injectable, plus oral Rybelsus — but no price you can see before the quiz.
Main trade-off: No per-molecule price — the advertised $199 is shared across all weight-loss treatments and per-dose rates are quiz-gated
Both molecules as dissolving tablets — and no way to find out what a small dose costs.
Main trade-off: No price anywhere on the public site — the pricing page is broken and every product CTA leads to an intake quiz, so the one thing a microdoser needs to know (what a fraction of a dose costs) cannot be established before signing up
Advertises one price for every dosage — and nine different starting figures, not one of which it attaches a term to.
Main trade-off: The flat-price finding here is Oak's own marketing rather than our inference: "One price · All dosages" and "All doses are the same price". Billed that way, someone holding at a starter dose pays exactly what someone at the top of the range pays — and Oak publishes no low-dose or microdose product to move to instead
Not one flat figure · No labs · Pharmacy not named · our Oak review
Calls its program a microdose and never publishes the dose — but weighs your muscle every week.
Main trade-off: No milligram figure is published anywhere — including on the page titled "Microdose GLP-1 Rx Program" and at the checkout, which says only that the provider sets the final dose. Nothing published anywhere tells you what dose $199 buys
Branded-first GLP-1 program with a microdose track, bundled into a coaching subscription.
Main trade-off: THE MONTH IS FOUR WEEKS. Billing is $537 per 12 weeks recurring, which is about $2,327 a year against the $2,148 that "$179/month" implies — roughly 8.3% more than the headline reads
Not one flat figure · Labs optional · Pharmacy network · our Noom Med review
Carries a named compounded-microdose-tirzepatide product inside the broadest multi-vertical catalog here — but won't say what it costs.
Main trade-off: No published price for the microdose tirzepatide product itself, or for standard tirzepatide, Zepbound, NAD+ or the hair-loss line — a microdoser cannot cost the one product that makes this listing relevant before starting an intake
A microdose page that renders no price at all — the figure exists only in the markup search engines read.
Main trade-off: The microdose page renders no price at all. The $99 is fed to search engines and shown in a comparison pop-up, but never printed on the page itself — and on at least one other product the site is built to hide the price the same way
Markets flat, transparent pricing on every treatment page, and publishes no price on any of them.
Main trade-off: Every treatment page markets flat, transparent pricing and no hidden fees while publishing no price whatsoever on that page — the GLP-1 Microdose has no figure at any tier, so the one product this site would send a reader here for cannot be cost-compared against anything
The only provider here that publishes an actual microdose milligram ladder — and no price for any GLP-1 product at all.
Main trade-off: Publishes no price for any GLP-1 product at any tier — semaglutide, tirzepatide and the microdose all say only "available by consultation" — while the peptide catalog on the same site carries per-molecule prices. It can publish a price and chooses not to on the products it leads with
Not one flat figure · No labs · Pharmacy not named · Dietitian included · our Metabolyz review
Calls its microdose protocol the reason members come to it, and publishes no price for it on the page that sells it.
Main trade-off: Three mutually inconsistent price sets ship at the same time: the hero advertises one figure, the pricing cards a second, and the site's own shipped data a third. The same drug carries two different prices depending on where on the page you look, and the hero figure matches no product at any tier
Approves you before it prices you, and never says what dose any of its plans buys.
Main trade-off: NO DOSE SITS BEHIND ANY PRICE. Not one milligram figure appears on the marketing pages, in the twenty-question assessment or on the screen you pay from, so someone intending to take a quarter dose cannot tell what they are buying or whether taking less changes anything
Publishes a floor and then makes the real number conditional on a provider review you have to start first.
Main trade-off: THE PRICE IS CONDITIONAL BY ITS OWN LABEL. "Plans from $199/mo" is annotated "confirmed after provider review", so the published figure is not a rate anyone is quoted — it is a floor pending an assessment
Sells a microdose program built for composition rather than the scale — and publishes no price for it.
Main trade-off: NO PRICE FOR THE MICRODOSE PROGRAM ANYWHERE. The program page publishes no dollar figure at all, so the one question this site exists to answer — what does a low dose cost here — cannot be answered before starting an eligibility check
Each figure is the provider's own published price, printed word for word — several of them bill a membership, a visit, or a lab panel on top of the medication, and “not one flat figure” is the tell. Verified against each provider's site in 2026; prices change without notice. Providers we have no commercial tie to get plain referral attribution rather than a paid link.
We compared the providers that actually offer a low-dose path on the things that matter once the marketing fades: a transparent price, genuine clinical review, and real human support. CoreAge Rx earns our top spot for value — flat $79–$129/month with doctor-reviewed protocols, 503A compounding, and included nurse and dietitian consults.
A note before you read on: intentional GLP-1 microdosing is currently off-label and unproven — there are no dedicated randomized trials of sub-therapeutic GLP-1 dosing. This ranking reflects provider value, transparency, and support, not a claim that microdosing is clinically proven. Start with our microdosing GLP-1 evidence review.
FTC disclosure. We have affiliate or referral partnerships with some of the providers ranked here, and may earn a commission at no extra cost to you when you start through one of our links. Every provider on this page — partner or not — gets the same write-up, the same trade-offs and the same button; only the link target and its rel differ. The case for each provider is written out on its card, trade-offs included and no softer for a provider that pays us, so you can weigh the argument rather than the position. See our full disclosure.
Our #1 pick
$79–$129/mo flat
1
CoreAge Rx
Doctor-reviewed low-dose GLP-1 protocols with flat pricing and built-in human support.
U.S.-licensed clinicians review an online intake, then a low-dose GLP-1 protocol is filled by a 503A compounding pharmacy. CoreAge runs two longevity-oriented programs: a Semaglutide Microdose (up to 0.125 mg, $79/mo) and a Tirzepatide Microdose (dual GIP/GLP-1, up to 1.25 mg, $129/mo), framed for metabolic baseline and appetite — not aggressive weight loss. Every plan includes 1:1 nurse and registered-dietitian consults, an automatic refund if you are not approved, and roughly 2-business-day shipping. Monthly recurring, with no separate membership or lab fee.
Strengths
Transparent flat pricing — $79/mo semaglutide, $129/mo tirzepatide, with no membership or lab surcharge
Doctor-reviewed protocols filled by a 503A compounding pharmacy
Included 1:1 support from nurses and registered dietitians
Automatic refund if you are not approved for treatment
Explicit low-dose, longevity-and-metabolic framing rather than max-dose weight-loss marketing
Trade-offs
Focused on low-dose metabolic protocols — not a full-titration weight-loss clinic
Like all compounded GLP-1s, the product is not FDA-approved, and intentional microdosing is off-label and unproven (see our evidence review)
Start with CoreAge Rx — from $79/moMicrodosing is off-label and unproven — decide with a clinician. Prices verified in 2026; confirm current terms.
The rest of the field
Real telehealth providers that verifiably offer a low-dose GLP-1 path, each checked against their own site in 2026. We only state a price where the provider published one we could confirm; where pricing is gated behind an eligibility request, we say so.
Every provider is listed in the price groups above, with its published price and a link to the full review.
Three narrower questions, answered separately
The ladder above is the whole field. If your question is sharper than “who should I use”, these rankings scope to it — and two of them reorder the same providers on a basis this hub does not use, ranking on whether a company charges you less when you take less rather than on its headline monthly rate.
Only the providers that publish a tirzepatide price you can read before an intake, sorted by what that price does at a quarter dose. The six that sell tirzepatide and will not say what it costs are named rather than ranked.
Every provider here with a route other than an injection. It opens with the part the category buries: there is no FDA-approved oral tirzepatide, and most of what is sold under that name has no absorption data behind it at all.
Want the side-by-side again? Back to the price ladder — every provider, price, pharmacy and lab requirement on one screen. “Optional” labs means the provider may offer or suggest testing but does not gate the basic plan on it. Confirm current terms with the provider before starting.
Why CoreAge Rx ranks first
CoreAge wins on the fundamentals rather than on any claim that microdosing is a miracle. The price is genuinely flat — $79/month for the Semaglutide Microdose and $129/month for the Tirzepatide Microdose — with no membership or lab surcharge to discover later. The intake is reviewed by U.S.-licensed clinicians, the medication is filled by a 503A compounding pharmacy, and every plan includes 1:1 consults with nurses and registered dietitians. If you are not approved, you are refunded automatically.
We are also honest about the science: there are no dedicated trials showing that intentionally microdosing GLP-1s delivers the metabolic benefits seen at therapeutic doses, and compounded GLP-1s are not FDA-approved products. This ranking is about provider quality, value, and experience — not a promise of results. Read the full picture in our microdosing GLP-1 evidence review before deciding.
Some of the providers here pay us a commission when a reader starts through our link, and we say so at the top of the ladder as well as in our disclosure; what we write about a provider is the same either way. We weigh the four factors below, with price transparency carrying the most weight because hidden recurring fees are the most common way GLP-1 programs end up costing more than they first appear. None of this makes microdosing itself proven — it is off-label, with no dedicated randomized trials, and we rank provider value, not outcomes.
Price transparency
We reward a single, all-in monthly price. Plans that stack a membership or lab fee on top of the medication price rank lower than a true flat rate.
Clinical oversight
Real review by U.S.-licensed clinicians of an online intake, with a clear path to decline patients who are not appropriate candidates for a GLP-1.
Pharmacy quality
We note whether the compounding pharmacy is identified (e.g. a 503A facility) rather than left vague.
Human support
Included access to nurses or registered dietitians — not just a shipped vial — meaningfully improves the experience and the safety of a metabolic protocol.
Read the evidence first
A provider ranking is only half the decision. Understand what low-dose GLP-1 dosing can and cannot do before you start:
This page is informational and not medical advice. GLP-1 medications are available by prescription after clinician review; compounded GLP-1s are not FDA-approved, and intentional microdosing is off-label with no dedicated clinical trials. Talk to a licensed provider about whether it is appropriate for you.